DILANTIN-125 SUSPENSION 125 MG / 5 ML — DIN 00023450
PHENYTOIN : 125 MG / 5 ML · BGP PHARMA ULC · SUSPENSION · wholesale supply in Canada
Health Canada status: CANCELLED POST MARKET
What is DILANTIN-125 SUSPENSION?
DILANTIN-125 SUSPENSION 125 MG / 5 ML contains PHENYTOIN : 125 MG / 5 ML. It is listed in the Health Canada Drug Product Database under DIN 00023450, held by BGP PHARMA ULC, supplied as SUSPENSION for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 09-Dec-2025. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
How much does Phenytoin cost around the world?
Phenytoin is listed on 6 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Greece publishes a producer price (ex-factory); Romania publishes a max producer price. Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| United States | acquisition | 3 | 9 | USD███.██ |
| Australia | ex-manufacturer | 3 | 8 | AUD███.██ |
| South Africa | single exit price | 6 | 6 | ZAR███.██ |
| Greece | producer price (ex-factory) | 3 | 3 | EUR███.██ |
| Romania | max producer price | 2 | 3 | RON███.██ |
| United Kingdom | hospital | 2 | 2 | GBP███.██ |
31 pack listings across 19 brand entries and 6 price bases, refreshed 08 Sep 2026. Ranges span every Phenytoin pack in that market, so a high figure is usually a larger pack rather than the same product.
This table is a regulatory record of where the molecule is listed. The DIN on this page is no longer authorized for sale in Canada, so Nexara does not quote it — see the alternatives above.
Is there a generic Phenytoin in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
9 holders have a Canadian DIN containing Phenytoin, across 14 DINs, of which 7 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| BGP PHARMA ULC | 5 | 3 | DILANTIN, DILANTIN INFATABS, DILANTIN-125 SUSPENSION, DILANTIN-30 SUSPENSION | Sourceable in Canada |
| TARO PHARMACEUTICALS INC | 2 | 1 | TARO-PHENYTOIN | Sourceable in Canada |
| AA PHARMA INC | 1 | 1 | PHENYTOIN SODIUM | Sourceable in Canada |
| HIKMA CANADA LIMITED | 1 | 1 | PHENYTOIN SODIUM INJECTION USP | Sourceable in Canada |
| SANDOZ CANADA INCORPORATED | 1 | 1 | PHENYTOIN SODIUM INJECTION USP | Sourceable in Canada |
| NOVOPHARM LIMITED | 1 | 0 | NOVO-PHENYTOIN CAP 100MG | No marketed DIN |
| OMEGA LABORATORIES LIMITED | 1 | 0 | PHENYTOIN SODIUM INJECTION USP | No marketed DIN |
| PARKE-DAVIS DIVISION, WARNER-LAMBERT CANADA INC. | 1 | 0 | DILANTIN INJ 50MG/ML | No marketed DIN |
| PFIZER CANADA ULC | 1 | 0 | PHENYTOIN SOIDUM INJECTION USP | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 125 MG / 5 ML |
|---|---|
| Dosage form | SUSPENSION |
| Route | ORAL |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Phenytoin |
|---|---|
| ATC code | N03AB02 |
| AHFS class | 28:12.12 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 00023450 |
|---|---|
| DIN (unpadded, as printed on some documents) | 23450 |
| Brand name | DILANTIN-125 SUSPENSION |
| Generic / active ingredient | PHENYTOIN : 125 MG / 5 ML |
| Market authorization holder | BGP PHARMA ULC |
| Health Canada schedule | Prescription |
| ATC code | N03AB02 |
| ATC anatomical main group | N — Nervous system |
| ATC therapeutic subgroup | N03AB |
| Current status | CANCELLED POST MARKET |
| Status date | 09-Dec-2025 |
| Original market date | 1953-12-31 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
Is Phenytoin in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Active — reported by HIKMA CANADA LIMITED, last seen 09 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
7 of 14 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| DILANTIN | 30 MG | CAPSULE | BGP PHARMA ULC | MARKETED | 00022772 |
| DILANTIN | 100 MG | CAPSULE | BGP PHARMA ULC | MARKETED | 00022780 |
| DILANTIN INFATABS | 50 MG | TABLET (CHEWABLE) | BGP PHARMA ULC | MARKETED | 00023698 |
| PHENYTOIN SODIUM | 100 MG | CAPSULE | AA PHARMA INC | MARKETED | 02460912 |
| PHENYTOIN SODIUM INJECTION USP | 50 MG | SOLUTION | HIKMA CANADA LIMITED | MARKETED | 02431378 |
| PHENYTOIN SODIUM INJECTION USP | 50 MG | LIQUID | SANDOZ CANADA INCORPORATED | MARKETED | 00780626 |
| TARO-PHENYTOIN | 125 MG / 5 ML | SUSPENSION | TARO PHARMACEUTICALS INC | MARKETED | 02250896 |
| DILANTIN INJ 50MG/ML | 250 MG / 5 ML | LIQUID | PARKE-DAVIS DIVISION, WARNER-LAMBERT CANADA INC. | CANCELLED POST MARKET | 00245453 |
| DILANTIN-30 SUSPENSION | 30 MG / 5 ML | SUSPENSION | BGP PHARMA ULC | CANCELLED POST MARKET | 00023442 |
| NOVO-PHENYTOIN CAP 100MG | 100 MG | CAPSULE | NOVOPHARM LIMITED | CANCELLED POST MARKET | 00037435 |
2 · Same class — other molecules in ATC N03AB
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Phenytoin | DILANTIN · DILANTIN INFATABS · DILANTIN INJ 50MG/ML · DILANTIN-125 SUSPENSION · +6 more | 14 | 7 | Yes |
| Fosphenytoin | CEREBYX | 1 | 1 | Yes |
| Phenytoin, Combinations | DILANTIN W PHENOBARBITAL 15MG · DILANTIN W PHENOBARBITAL 30MG CAP | 2 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC N03A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| N03AX | Brivaracetam · Cannabidiol · Cenobamate · Lacosamide · Lamotrigine · +4 more | 391 | 197 |
| N03AF | Carbamazepine · Eslicarbazepine · Oxcarbazepine · Rufinamide | 86 | 33 |
| N03AG | Valproic Acid · Vigabatrin | 75 | 19 |
| N03AA | Phenobarbital · Primidone | 39 | 13 |
| N03AE | Clonazepam | 55 | 8 |
| N03AD | Ethosuximide · Mesuximide | 5 | 4 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is DILANTIN-125 SUSPENSION called?
The same molecule, Phenytoin, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Dilantin Sodium | Latin | Australia |
| Dilantin | Latin | Australia |
| Dilantin Infatabs | Latin | Australia |
| Epanutin Forte Suspension | Latin | South Africa |
| Epanutin Infatabs | Latin | South Africa |
| Phenytoin | Latin | South Africa |
| Phenytoin Sodium | Latin | South Africa |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.